Back to the presentation

The Strategic Opportunity

What Exactly Would the License Deliver?

Access rather than ownership: three years of a working platform shaped around our use cases, with a custom user experience, integration support and validation on our own data. Source code, model weights and ownership stay with the provider.

Main finding

The three-year budget splits into access ($12M), integration and customization ($5M), and validation and deployment ($3M). It buys a customized right to use an existing platform, not ownership of it, and the proposal is presented as an opportunity rather than a confirmed commercial term.

What supports it

  • The internal cost model reproduces the split arithmetically; the three components sum to the stated total without overlap.
  • Licensing practice separates access, integration and enablement, because each is delivered by a different team at a different time.
  • Access is the largest share because the underlying capability already runs and its cost was carried by the provider.
  • Validation is the smallest line but the one that decides whether the licence is renewed.

What this does not claim

  • No supplier quotation exists. Every figure is a preliminary planning estimate that negotiation may move materially.
  • Ownership of the technology, model weights and source code stays with the provider, and the right ends with the term.
  • Nothing here is an offer, a commitment to purchase or a valuation of the technology.

Planning assumptions used

  • A single three-year term, with customization scoped to the six priority applications.
  • Validation and enablement cover our data integration, testing and staff training.
  • All figures remain unconfirmed planning assumptions.

Open before signature

  • What happens to the customized layer at the end of the term?
  • Are overage fees, additional users or new models priced separately?
  • Which deliverables convert from estimate to milestone payment at signature?

Sources

Figures marked illustrative are planning assumptions. This note separates published evidence from project assumptions and does not present a supplier quotation, a valuation or a forecast of returns.